A Milestone in Neuromuscular Care: AGAMREE® (vamorolone) Approved as the First Treatment for Duchenne Muscular Dystrophy in Canada
Health Canada has approved AGAMREE® (vamorolone), marking the first-ever treatment for Duchenne Muscular Dystrophy (DMD) in Canada!
Granted under Health Canada’s Priority Review process, this approval represents its potential to significantly impact the lives of those affected by the debilitating disease. This is a landmark moment for families and clinicians, advancing the mission to raise the standard of care, improve access to therapies, and support those living with Duchenne across the country.
- AGAMREE® is approved for boys aged 4 years and older, with no upper age limit.
- The AGAMREE® Patient Support Program opens for enrollment on October 10, 2025.
“Given the significant unmet need of individuals with DMD, I am pleased that AGAMREE® has received priority review and is now approved by Health Canada. As AGAMREE® has no impact on linear growth and showed favourable changes in serum bone turnover biomarkers, it provides families with a viable treatment option compared to other corticosteroids.”
— Dr. Jean Mah, Director of the Pediatric Neuromuscular Program at the Alberta Children’s Hospital and NMD4C Investigator
“For too long, Canadian families have watched treatment advances unfold elsewhere while waiting for options here at home. With this approval, a new era of innovative therapies and treatments for Duchenne begins. This milestone is cause for celebration, while the continued focus remains on ensuring that AGAMREE® is not only approved, but also reimbursed and accessible to every Canadian who needs it.”
— Dr. Homira Osman, VP of Research & Public Policy, Muscular Dystrophy Canada & NMD4C Steering Committee Co-Chair
“This is an exciting day for Canadians and many Duchenne parents join in celebrating the very first treatment approved in Canada. It is thanks to the collaborative efforts of all who have been involved in bringing this treatment to fruition. The hope is that this is the first of many treatment options that will become available to Canadians living with Duchenne.”
— Nicola Worsfold, Executive Director, Defeat Duchenne Canada
This achievement is a testament to the power of collaboration among researchers, clinicians, families, and advocacy organizations. It reflects our collective commitment to raising the standard of care, improving access to therapies, and building research capacity across Canada.
Read next...
Scheduled Maintenance
Please note that this website, imPORTND, and the NNLS training platform will undergo maintenance from July 23 until July 27, 2026.
Discover Neuromuscular Talent Across Canada
The NMD4C Neuromuscular Talent Pool is now live with new trainees! We invite supervisors and research groups to explore the Talent Pool to identify candidates whose skills, experience, and interests align with your work and upcoming positions. Trainees interested in being included in the Neuromuscular Talent Pool can register by completing the short form, uploading a CV and brief personal statement outlining their experience, interests, and career goals. For more information and to access the Talent Pool, please visit our website.
Join Us at the 2026 NMD4C Annual Meeting on 25 September
The 2026 NMD4C Annual Meeting will take place in Calgary on Friday, September 25, 2026. The agenda will feature a brief network update, trainee and early-career recognitions, flash talks, a health economics research showcase, and a series of cross‑disciplinary and parallel clinical/pre‑clinical discussion sessions to explore key topics, including advocacy and therapy access, strategies to sustain and strengthen pre-clinical programs, and network sustainability and strategic planning.